WHO Says Flu, COVID-19 Symptoms Overlap

Health officials say symptoms cannot reliably identify which respiratory virus is causing an infection, and a new variant has drawn research attention.

Updated on Nov. 9, 2026 in COVID-19

Bold flat-color editorial illustration of three unlabeled glass vials with similar pale clusters on a matte surface, evoking respiratory symptoms that look alike.
The World Health Organization said flu and COVID-19 symptoms overlap so closely that they cannot reliably identify which respiratory virus is causing an infection. AI Illustration. Upload story photo >

Live Poll

Would you get tested before deciding a cold-like illness is COVID or flu?

The World Health Organization said symptoms of COVID-19, influenza and other respiratory infections overlap and cannot reliably identify the causative virus. Separately, a Journal of Infection study reported that the PJ.2.1 variant showed more efficient cell entry and reduced antibody neutralization in laboratory experiments.

Why it matters

Because common respiratory illnesses look similar, testing may be needed when identifying the cause could affect treatment or public health responses. Laboratory findings on PJ.2.1 point to the need for continued surveillance of the virus's evolution.

The figures come from laboratory pseudovirus experiments comparing PJ.2.1 with the LP.8.1 reference variant, showing 1.5 to 2.5 times greater cell-entry efficiency in four of five cell lines and about 1.8 times lower antibody neutralization. Whether these lab differences translate into real-world transmission or severity has not been established.

The players

World Health Organization

The WHO is the United Nations agency responsible for international public health, which issued guidance on the overlapping symptoms of respiratory infections.

Journal of Infection

A peer-reviewed medical journal that published the laboratory study examining the PJ.2.1 variant's cell entry and antibody evasion.

The details

Researchers tested how PJ.2.1 interacts with human cells, its reliance on the ACE2 receptor, and its ability to evade vaccine-induced antibodies. Researchers suggested increased ACE2 binding could help the variant infect cells with lower receptor levels.

Timeline

  1. May 2, 2026: PJ.2.1 was first detected in Ontario, Canada.

  2. October 24, 2026: The Journal of Infection published the PJ.2.1 study online.

  3. November 8, 2026: WHO issued its statement on symptom overlap and testing.

Big Picture

The PJ.2.1 findings extend the WHO's ongoing genomic surveillance of SARS-CoV-2 lineages, which tracks how individual variants evolve and spread over time. Laboratory results like these feed into that monitoring to flag variants that may warrant closer attention.

Because COVID-19, flu and other respiratory infections share symptoms like fever, cough and fatigue, a positive test may be needed to know which virus is behind an illness. Rapid antigen tests can indicate an active infection, though confirming a specific variant like PJ.2.1 requires genetic analysis.

The takeaway

Symptoms alone cannot tell you which respiratory virus you have, so testing is the reliable way to identify the cause when it matters. Staying informed about variant research helps readers understand why testing guidance can change over time.

Further reading

Explore more on COVID-19 and how variants are tracked worldwide.

Live Poll

Would you get tested before deciding a cold-like illness is COVID or flu?